@FiercePharma: More Novo Nordisk bad news: Loses Prandin patent fight in U.S. Circuit Court, $200m sales at risk. Report | Follow @FiercePharma
@EricPFierce: U.K. gets nervous on looming deadline for API certifications, outlines contingency plan. Yesterday's report | Follow @EricPFierce
> Royalty Pharma threw in the towel Tuesday, dropping its four-month, $6.7 billion takeover run for Irish drug company Elan ($ELN). Story
> Actavis ($ACT) and Kissei Pharmaceutical are suing Sandoz and Hetero for infringing the patent on Rapaflo, a treatment for benign prostatic hyperplasia (BPH). Release
> The two thrombosis drug brands, Arixtra and Fraxiparine, that GlaxoSmithKline ($GSK) is talking about selling to South Africa's Aspen Pharmacare could be worth $1 billion. Story
> A U.S. court has slapped down a patent for Novo Nordisk's ($NVO) Prandin, a move that paves the way for generics of the combo with metformin for treating diabetes. Story
> Protalix BioTherapeutics said Wednesday that it has a 7-year deal with Brazil to sell the country $280 million worth of its Gaucher disease drug, Uplyso, known as Elelyso in the U.S. Story
> Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN) reported today that results of a study looking for additional benefits for their Type 2 diabetes drug Onglyza found that it was no better than a placebo at reducing heart attacks, strokes, or death from cardiovascular causes. Story
@FierceMedDev: Editor's Corner: Germany's Epigenomics is betting its future on an early-detection colon cancer Dx. Feature | Follow @FierceMedDev
@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. Yesterday's story | Follow @DamianFierce
> Techne grabs Bionostics for $104M. Item
> Terumo adding 400+ jobs in R&D expansion. Report
> CryoLife eyes FDA approval for dissolving hemostat. Item
> Mirabilis nabs up to $13M for uterine fibroid device. Report
> OrthoSensor wins FDA nod for knee tech. Article
Biotech News
@FierceBiotech: Join what is probably one of the fastest-growing LinkedIn groups in biotech, & learn the meaning of life... sciences. Join now | Follow @FierceBiotech
@JohnCFierce: Man, oh man. Bluebird IPO busts out, raises $101M as biotech offerings turn red hot - $BLUE up 50%. News | Follow @JohnCFierce
@RyanMFierce: W/ $BLUE out, DMD drug developer Prosensa moves up in the biotech IPO queue, sets terms for $60M deal: More | Follow @RyanMFierce
@EmilyMFierce: This week's issue of FierceBiotechResearch is out: Alzheimer's drug restores links in brain and more: This week's news | Follow @EmilyMFierce
> Sarepta shares spike on upbeat results from DMD extension study. News
> NIH backs pharma giants and academics' projects to revive R&D castoffs. Article
> Analysis: AMA decision on obesity will boost drug R&D in a troubled field. Editor's corner
> Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround. Story
Drug Delivery News
@MichaelGFierce: Self-propelled, spinning 'nano-necklaces' could pinpoint drug delivery. More | Follow @MichaelGFierce
> BD, JDRF partner to join artificial pancreas race. More
> Capsugel launches Lipidex platform for greater oral stability, potency. Item
> Teva grabs MicroDose respiratory biz with inhaled delivery platform. Article
> Drug-carrying "nanovolcanoes" make precise delivery structures. Story
And Finally... The American Medical Association (AMA) kicked aside a committee recommendation and voted to designate obesity a disease, a move that may boost the fortunes of the new obesity drugs, Qysmia from Vivus ($VVUS) and Belviq from Arena ($ARNA). Story